Minimum clinically important difference in Quantitative Lung Fibrosis score associated with all-cause mortality in idiopathic pulmonary fibrosis: subanalysis from two phase II trials of pamrevlumab

By sjmartinez • May 13, 2025

Kim GH, Zhang X, Brown MS, Poole L, Goldin J. Minimum clinically important difference in Quantitative Lung Fibrosis score associated with all-cause mortality in idiopathic pulmonary fibrosis: subanalysis from two phase II trials of pamrevlumab. BMJ Open. 2025 May 12;15(5):e094559. doi: 10.1136/bmjopen-2024-094559. PMID: 40355288.

Tags: Chest imaging, Computed tomography, interstitial lung disease, Patient reported outcome measures, Publications, Pulmonary Disease, Pulmonary, Critical Care & Sleep Medicine, QUALITATIVE RESEARCH

Probing effect modification by socioeconomic status in associations between blood biomarkers of neuropathology and cognitive outcomes in the United States and India

Nichols E, Kim JK, Aksman LM, Gross AL, Hu P, Kobayashi LC, Thyagarajan B, Lee J, Crimmins EM. Probing effect modification by socioeconomic status in[...]

Effectiveness of brodalumab in biologic-experienced adults with moderate to severe plaque psoriasis: a focused narrative review

Armstrong AW, Strober BE, Liu CM, Cather JC, Merola JF, Lebwohl MG. Effectiveness of brodalumab in biologic-experienced adults with moderate to severe plaque psoriasis: a[...]

Biodistribution, shedding, and transmissibility of vusolimogene oderparepvec (RP1)

Wise-Draper TM, Robert C, Wong MK, Middleton MR, Sacco JJ, In GK, Muñoz Couselo E, Schadendorf D, Beasley GM, Niu J, Chmielowski B, Milhem MM,[...]